Nimble Therapeutics, now part of AbbVie, leverages deep immunology expertise to discover and develop novel medicines for immune‑mediated diseases. Its patient‑centric approach integrates real‑world data, advanced target validation, and AbbVie’s global clinical resources to accelerate precise, diverse therapeutic candidates. The company aims to provide clinicians with new treatment options and improve outcomes for patients across varied populations.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with immune-mediated diseases often lack effective, targeted therapies, and existing drug development processes may not fully address the diversity of patient populations or prioritize patient-centric outcomes.
Solution
Nimble Therapeutics, now part of AbbVie, applies its deep immunology expertise to discover and develop novel medicines that target unmet needs in immune‑mediated conditions. The company emphasizes a patient‑centric discovery and development approach, integrating advanced scientific platforms with real‑world patient insights to accelerate candidate selection. By leveraging AbbVie’s global resources and infrastructure, Nimble advances compounds through preclinical and clinical stages with a focus on safety, efficacy, and broader applicability across diverse patient groups. The resulting therapeutics aim to improve disease management and quality of life for patients while providing clinicians with new treatment options.
Target Audience
Primary customers are pharmaceutical partners and clinical researchers seeking innovative immunology therapeutics, as well as patients and healthcare providers treating immune‑mediated diseases.
Features
- Extensive immunology research expertise and legacy in immune‑mediated disease biology
- Patient‑centric discovery workflow that incorporates patient data and feedback early in development
- Advanced target validation and biomarker platforms to enhance precision of candidate selection
- Integrated pipeline management using AbbVie’s global clinical and regulatory capabilities
- Commitment to developing therapies for diverse patient populations, including under‑represented groups
- Collaborative partnership model that enables external academic and biotech collaborations